<DOC>
	<DOCNO>NCT00418821</DOCNO>
	<brief_summary>The purpose study determine laronidase present breast milk post-partum woman receive Aldurazyme® ( laronidase ) effect Aldurazyme ( laronidase ) growth , development , immunologic response breastfed infant .</brief_summary>
	<brief_title>A Study Effect Aldurazyme® ( Laronidase ) Treatment Lactation Female Patients With Mucopolysaccharidosis I ( MPS I ) Their Breastfed Infants</brief_title>
	<detailed_description>Recruitment limit facility list ; facility yet active may add upon identification patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Inclusion Criteria ( Mothers ) : The patient must document laronidase deficiency fibroblast , plasma , serum , leukocyte , dry blood spot laronidase enzyme activity assay . Be pregnant , plan breastfeed postpartum , receive Aldurazyme ( laronidase ) therapy breastfeeding . Provide sign , write informed consent prior protocolrelated procedure . Consent legally authorize guardian ( ) ( ) require mother young 18 year age . If mother 18 year old understand consent , write informed consent require mother authorized guardian ( ) . Provide sign , write informed consent infant participate study patient . If mother young 18 year age , consent mother infant obtain legal guardian . Exclusion Criteria ( Mothers Infants ) : Have medical condition , serious intercurrent illness , extenuate circumstance may interfere study compliance , include prescribed evaluation followup activity . Have receive investigational drug within 30 day prior study enrollment .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>